Increased Use of Recombinant and Prophylaxis Therapies Drives Growth
This research service focuses on the global haemophilia therapeutics market, with a particular focus on recently FDA-approved drugs and late-stage compounds for the treatment of haemophilia A, haemophilia B, inhibitors, and von Willebrand Disease. Pipeline analysis outlines the major FDA-approved haemophilia products, which include those submitted for regulatory review and those in Phase I, II, and III of clinical development. The study also provides an overview of the major clinical trials of recently approved or late-stage pipeline candidates. Novel technologies to extend product half-life and potential future therapies for haemophilia patients have also been discussed.
Regulatory Approaches to Combat Microbial Resistance and Stimulate Antibiotics R&D
Drug-resistant bacteria, or superbugs, pose a serious threat to human health. Developing new antibacterial drugs requires a great deal of time, effort, expenditure, and scientific research, making it a less-attractive segment for investment by pharmaceutical companies. This research service focuses on the global antibacterial drugs (antibiotics) market, with particular focus on the antibiotics currently under development. A list of currently available and marketed antibacterial drugs under the approved antibacterial drug classes has been provided. Product and pipeline assessment for recently approved antibacterial drugs, antibacterials under FDA review, as well as phase 3 antibacterial drug candidates have been provided. A detailed overview of the various regulatory approaches to foster innovation in the development of new antibiotics has been provided as well.
Rapid Economic Development and Healthcare Reforms Set the Stage for the Future
The Turkish pharmaceuticals segment is the 14th largest worldwide and the 6th largest in Europe, valued at $14.04 billion in 2013 and projected to grow at a CAGR of 9.1% from 2013 to 2018. Growth is driven by expanding public insurance, modernisation, prevalence of chronic diseases, increasing health awareness, and affluence. Market segmentation is based on products (e.g., over-the-counter, generic, and patented drugs) and therapeutic areas (e.g., antibiotics, anti-rheumatics, cardiovascular, analgesics, oncology, cough preparations, and central nervous system). The study provides a macroeconomic overview of Turkey's mergers and acquisitions/investment trends, regulatory environment, revenue forecasts, key trends, and companies to watch.
A ripe business opportunity for big pharma and generic pharma companies
The pharmaceutical industry in Ghana and Nigeria is forecast to represent a combined business opportunity of over $3 billion by 2018, propelled by a convergence of changing economic profiles, increased healthcare spending and investment, and increasing incidence of chronic diseases. Market segmentation is done based on products (OTC, generic, and branded) as well as therapeutic areas (anti-infectives, cardiovascular, diabetes, oncology, respiratory, and CNS).
This study provides a detailed analysis that includes market overview, market engineering measurements, revenue forecasts, competitive analysis, and key trends for the pharmaceutical industry in Ghana and Nigeria.
A New Era in Human Health to Resolve Unmet Medical Needs
While a vast majority of currently available treatments for chronic and fatal diseases are palliative or delay disease progression, regenerative medicine is uniquely capable of altering the underlying disease. Although regenerative medicine is in a relatively early stage of development, a significant number of products, particularly cell therapy (CT)-based products and tissue engineered (TE) products, are already commercially available on the market.
This research service focuses on the 4 broad segments of the regenerative medicine market, namely cell therapy, gene therapy, tissue engineering, and small molecules and biologics. A detailed overview of the cell therapy segment, including the major commercialized products and products in development, has been provided. Additionally, key clinical milestones, timelines of key clinical events, key companies to watch, and a strategic partnership assessment in the global regenerative market have been included. An overview of the other segments-gene therapy, tissue engineering, and small molecules and biologics-has also been provided.
Persistent Unmet Need for Treatment Fuels Novel Antiviral/ Antibacterial Drug Development
This research service focuses on antibiotic/antibacterial therapeutics for the treatment of infection by blood-borne (sexually transmitted) bacteria, which include Chlamydia trachomatis and Neisseria gonorrhoea as well as antiviral therapeutics for infections by vector-borne pathogens such as the influenza virus and the human respiratory syncytial virus (RSV).This research service comprises of a product and pipeline assessment for marketed and investigational products and combination regimens for the treatment of Chlamydia trachomatis, Neisseria gonorrhoea, Influenza and RSV infections. Segmentation by drug class is provided along with additional supporting information, such as clinical trial timelines, results, and epidemiology.
Market Opportunities for Differentiated Therapeutics
Type 2 Diabetes is one of the most significant global health concerns of modern times. The size of the diabetes therapeutics market has stimulated a vast and growing pipeline of potential new therapies aimed at the unmet needs of tighter glucose control, improved safety profiles, and greater convenience to patients.
This research service evaluates the global market for the pharmaceutical management of type 2 diabetes from 2009 to 2017, with 2012 as the base year. Segmentation by drug type (insulin and non-insulin therapeutics) and regional breakdown are provided. Included are products available in the market, products in development, and patient and revenue forecasts. Market challenges, drivers, and restraints are identified and assessed.
Injectable Dose Formulations will Likely Spur the Growth of CMOs
The global pharmaceutical contract manufacturing market remains highly fragmented with many contract manufacturing organizations (CMOs) relying on one client for more than 50 percent of their revenue. To maintain a competitive edge amidst stiff competition, CMOs are striving to provide a greater value proposition for clients by engaging in early life-cycle stage projects and establishing long-term relationships. Promoting additional services such as formulation improvements, alternate dose forms, real-time order tracking, and logistics support will also be necessary to attract new customers.
Market segments covered in this research service include solid dose formulations, liquid and semi-solid dose formulations and injectable dose formulations. Revenue forecasts and in-depth analysis of the global, U.S. and European CMO markets have been featured in this report.
An Overview of Promising Drugs and Innovations in the Haematology Therapeutics Market
The global haematology therapeutics market is broadly divided into two types: drugs used to treat malignant blood disorders and drugs used to treat non-malignant disorders. The scope of this study includes drugs used to treat non-malignant blood disorders only. Drugs used to treat non-malignant blood disorders are classified into eight major segments, including antianaemics, anticoagulants, antifibrinolytics, fibrinolytics, blood substitutes, plasma expanders, platelet aggregation inhibitors, and other haematologicals.
This market insight provides the list of key marketed products as well key compounds in phase 2 and 3 clinical trials in the global nonmalignant blood disorders market. Additionally, an overview of the major on-going phase 3 clinical trials and detailed findings of most promising phase 3 compounds have also been provided.
Technology Innovation and Product Differentiation are Crucial for Increasing Market Shares
With more than 80% of the target population for hGH being children below the age of 15 years, taking hGH injections on a daily basis is a major challenge. This has led to poor adherence and higher withdrawal rates from existing therapeutic regimes. Companies have increasingly started to focus on developing non-invasive delivery methods to improve patient compliance and reduce treatment withdrawal rates. Product differentiation in the hGH market is aimed at 3 different levels; namely, drug delivery mechanisms, long-acting preparations and improved formulations, and combination therapy.
The research service provides an analysis and an assessment of the European human growth hormones market. It maps the key trends and dynamics shaping the industry sector, and provides pipeline analysis, valuable insights on competitive landscape, and strategic recommendations for the success of the market participants. Moreover, the study provides an in-depth analysis of the European human growth hormones market, in terms of the adult and pediatric human growth hormone segments with specific focus on seven key regions-Germany, France, the United Kingdom, Italy, Spain, Scandinavia, and Benelux, highlighting the regulatory policies in each region.
Launch of Disease-modifying Drugs expected to Boost Market Growth
Increasing R&D activity and a strong pipeline of disease modifying drugs bode well for expansion of the Alzheimer's Disease Medication Market. Existing drug classes for AD offer poor therapeutic efficacy. The core focus of new R&D approaches has therefore centered on novel disease modifying drugs, which are expected to offer potential benefits over conventional therapeutic options as they are safer, more effective and aim to prevent or slow down disease progression rather than provide just symptomatic relief.
The key objective of this research service is to study the European Alzheimer's disease medication market based on the three major classes of drugs namely acetylcholinesterase inhibitors, NMDA receptor antagonists and new mechanism/ disease modifying drugs and identify the key current and future trends shaping these market segments. It also aims to provide valuable insights on the potential drug candidates in the pipeline and analyze the competitive landscape with respect to the key existing market participants and promising companies in the future. Revenue forecasts of total market as well as key five European countries are also provided.
Novel Technology Innovations and Therapeutic Vaccines are Likely to Revolutionize the Industry
As vaccine manufacturers increasingly tend to leverage on novel technologies, and potential late-stage vaccine candidates progress the pipeline and reach the commercialization stage, the European vaccines market is expected to witness significant growth rates. The vast majority of the vaccines in pipeline are novel, innovative vaccines based on new antigens, targeting malaria, tuberculosis, dengue fever, allergies and herpes. Anticipation of capacity demand remains a key challenge for vaccine manufacturers, particularly during pandemic outbreak of diseases.
This research service aims at analyzing the European Vaccines Market in terms of the key prophylactic infectious diseases as well as demographic classification. In addition to the detailed pipeline analysis, an overview of the novel technologies and therapeutic vaccines has also been provided.
Improving New Drug Formulations and Strong Product Pipelines Expected to Restore Growth beyond 2013
Over three million people have been diagnosed with some form (mania, hypomania or depression) of bipolar disorder in Europe; this number is estimated to double by 2018. Most of the currently approved drugs focus on the treatment of acute mania or hypomania, which means that drugs targeting bipolar depression are the need of the hour. Patent expiry of key blockbuster atypical antipsychotic drugs is likely to cause a decline in growth of the European bipolar disorder therapeutics market until 2013. However, approval of new drugs and improved depot formulations are expected to present growth opportunities from 2014 to 2018.
This research service tracks the key trends, growth drivers and restraints of the European Bipolar Disorder Therapeutics Market in 2011. A detailed analysis of the existing market players and promising companies in the future is provided. Additionally, an in-depth pipeline analysis of the four potential phase III compounds for bipolar disorder is also covered in this report.
Ripe for Growth and Opportunities: Several Key Blockbuster Drugs to go off-patent by 2014
The global generic pharmaceuticals market is likely to witness strong growth in the next few years owing to the patent expiry of key blockbuster drugs worth $150 billion and the judicious cost-containment efforts of governments and healthcare service providers worldwide. At the same time, the balance in terms of healthcare expenditure and sales revenues is poised to shift from developed to emerging markets like India, China, Brazil, Turkey, Russia and South Korea, as huge potential still remains untapped in these countries; as well as from commodity generics to less competitive yet commercially attractive segments such as difficult-to-produce generics, specialty generics and biosimilars.
This research service analyses the revenue prospects of the developed pharmaceutical markets such as the U.S and Europe as well as the emerging markets of India and China. The patent expiration timetable of key blockbuster drugs in the U.S. and Europe has also been listed. Furthermore, revenue forecasts and strategic recommendations for the success of market participants have been discussed.